Marcus Pilgerstorfer considers how EU regulation and litigation based on EU health law interact in the case of pharmaceuticals, leaving uncertainties in the legal position with potential policy implications. The chapter considers some principal interactions between the EU’s regulatory regime for medicinal products, and its system of civil liability for defective products – focusing on marketing authorisation, labelling and advertising, post-market obligations and the Product Liability Directive.
Other access options
Log in with Open Athens, Shibboleth, or your institutional credentials
Log in with your Elgar Online account